Veru Inc. (NASDAQ:VERU - Free Report) - Investment analysts at B. Riley reduced their Q4 2025 EPS estimates for shares of Veru in a note issued to investors on Wednesday, May 14th. B. Riley analyst W. Wood now expects that the company will post earnings of ($0.06) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Veru's current full-year earnings is ($0.22) per share. B. Riley also issued estimates for Veru's FY2026 earnings at ($0.24) EPS.
Veru Stock Performance
Shares of NASDAQ:VERU traded down $0.02 during midday trading on Monday, hitting $0.49. 1,227,319 shares of the stock were exchanged, compared to its average volume of 1,726,157. The company has a market capitalization of $71.81 million, a PE ratio of -1.88 and a beta of -0.74. Veru has a 52-week low of $0.45 and a 52-week high of $1.42. The business's fifty day simple moving average is $0.53 and its two-hundred day simple moving average is $0.62.
Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of VERU. MPM Bioimpact LLC grew its stake in shares of Veru by 53.8% in the 1st quarter. MPM Bioimpact LLC now owns 6,592,727 shares of the company's stock valued at $3,231,000 after buying an additional 2,307,362 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Veru by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,997,751 shares of the company's stock worth $1,950,000 after purchasing an additional 57,611 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Veru by 17.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,423,288 shares of the company's stock valued at $698,000 after purchasing an additional 206,614 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in shares of Veru by 18.3% in the 1st quarter. Oppenheimer & Co. Inc. now owns 1,325,246 shares of the company's stock valued at $650,000 after purchasing an additional 204,660 shares during the last quarter. Finally, PVG Asset Management Corp boosted its holdings in Veru by 64.4% in the fourth quarter. PVG Asset Management Corp now owns 1,047,310 shares of the company's stock worth $681,000 after purchasing an additional 410,340 shares in the last quarter. Hedge funds and other institutional investors own 47.16% of the company's stock.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Featured Articles
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
